Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/955"

Predicate	Value (sorted: default)
rdfs:label	"evidence_1489"
rdf:type	?:Evidence ?:Item
?:Evidence_enzyme_system	""
?:Evidence_type	?:Non_traceable_Drug_Label_Statement
?:content	""Cytochrome P450 3A4: In vitro and in vivo data indicate that rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent. This has been confirmed in studies with known cytochrome P450 3A4 inhibitors (ketoconazole, erythromycin, itraconazole). Ketoconazole: Coadministration of ketoconazole (200 mg twice daily for 7 days) with rosuvastatin (80 mg) resulted in no change in plasma concentrations of rosuvastatin. Erythromycin: Coadministration of erythromycin (500 mg four times daily for 7 days) with rosuvastatin (80 mg) decreased AUC and Cmax of rosuvastatin by 20% and 31%, respectively. These reductions are not considered clinically significant.""
dc:creator	"boycer"
dc:date	"09/28/2007 12:06:44"
rdfs:seeAlso	?:drugInfo.cfm?id=3249

The resource appears as object in one triple:

{ rosuvastatin_substrate_of_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1489 }

Context graph